52 related articles for article (PubMed ID: 21140395)
1. Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.
Krug M; Wichapong K; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2011 Jan; 6(1):63-72. PubMed ID: 21140395
[TBL] [Abstract][Full Text] [Related]
2. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
3. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
5. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
[TBL] [Abstract][Full Text] [Related]
6. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
7. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
9. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.
Harbinski F; Craig VJ; Sanghavi S; Jeffery D; Liu L; Sheppard KA; Wagner S; Stamm C; Buness A; Chatenay-Rivauday C; Yao Y; He F; Lu CX; Guagnano V; Metz T; Finan PM; Hofmann F; Sellers WR; Porter JA; Myer VE; Graus-Porta D; Wilson CJ; Buckler A; Tiedt R
Cancer Discov; 2012 Oct; 2(10):948-59. PubMed ID: 22874768
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
Nutt JE; O'Toole K; Gonzalez D; Lunec J
Eur J Cancer; 2009 Jun; 45(9):1684-91. PubMed ID: 19318229
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.
Hegymegi-Barakonyi B; Eros D; Szántai-Kis C; Breza N; Bánhegyi P; Szabó GV; Várkondi E; Peták I; Orfi L; Kéri G
Curr Opin Mol Ther; 2009 Jun; 11(3):308-21. PubMed ID: 19479664
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-anilino α-carbolines as novel Brk inhibitors.
Mahmoud KA; Krug M; Wersig T; Slynko I; Schächtele C; Totzke F; Sippl W; Hilgeroth A
Bioorg Med Chem Lett; 2014 Apr; 24(8):1948-51. PubMed ID: 24650640
[TBL] [Abstract][Full Text] [Related]
14. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
15. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors.
Bhuva HA; Kini SG
J Mol Graph Model; 2010 Aug; 29(1):32-7. PubMed ID: 20493747
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
19. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
